Jeff Schaffnit: Sanofi Highlights Progress in Hemophilia and ITP at ISTH 2026
Jeff Schaffnit, General Manager and Head of Rare Blood Disorders at Sanofi, shared a post on LinkedIn:
“Looking back on the last few days, it’s clear that this year’s ISTH 2026 marked not only an important moment to reflect on the progress being made across rare blood disorders but also a time to reinforce the collective commitment driving innovation forward for patients.
I’m proud of the momentum Sanofi continues to build across our Rare Blood Disorders portfolio, from advances in hemophilia to continued progress in Immune Thrombocytopenia (ITP), where ongoing research is reshaping how we think about disease control.
What stands out most to me is what these milestones represent: years of collaboration among researchers, clinicians, patient communities and teams across Sanofi, all working toward the same goal of improving the day-to-day lives of people living with rare blood disorders.
Thank you to everyone whose dedication to chasing the miracles of science continues to turn scientific progress into meaningful impact for patients and families.”
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 05:19Tania Ahuja: Apixaban in Abdominal Transplant Patients
-
Aug 31, 2026, 04:28Reza Hafidz Irawan։ Automated Antibody Titration With Erytra Eflexis
-
Aug 31, 2026, 04:17Safa Chenganath: Stenosis vs Thrombosis – Hemodialysis Vascular Access
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads